These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 29220291)

  • 1. Emerging Targeted and Immune-Based Therapies in Sarcoma.
    Pollack SM; Ingham M; Spraker MB; Schwartz GK
    J Clin Oncol; 2018 Jan; 36(2):125-135. PubMed ID: 29220291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for sarcomas.
    Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
    Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
    Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
    Front Immunol; 2021; 12():775761. PubMed ID: 34925348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of immunotherapy for sarcomas.
    Miwa S; Nishida H; Tsuchiya H
    Immunotherapy; 2017 Dec; 9(16):1331-1338. PubMed ID: 29185391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next frontiers in systemic therapy for soft tissue sarcoma.
    Yen CC; Chen TW
    Chin Clin Oncol; 2018 Aug; 7(4):43. PubMed ID: 30173533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
    Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
    Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapeutic approaches to sarcoma.
    Burgess M; Tawbi H
    Curr Treat Options Oncol; 2015 Jun; 16(6):26. PubMed ID: 25975445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.
    Toulmonde M; Penel N; Adam J; Chevreau C; Blay JY; Le Cesne A; Bompas E; Piperno-Neumann S; Cousin S; Grellety T; Ryckewaert T; Bessede A; Ghiringhelli F; Pulido M; Italiano A
    JAMA Oncol; 2018 Jan; 4(1):93-97. PubMed ID: 28662235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in Sarcoma: Future Horizons.
    Burgess M; Gorantla V; Weiss K; Tawbi H
    Curr Oncol Rep; 2015 Nov; 17(11):52. PubMed ID: 26423769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
    Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
    Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas.
    Martín-Broto J; Moura DS; Van Tine BA
    Clin Cancer Res; 2020 Nov; 26(22):5801-5808. PubMed ID: 32601077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging Trends in Immunotherapy for Adult Sarcomas.
    Husain M; Chen L; Liebner D; Beane J; Rubinstein M; Pollock R; Verschraegen C; Tinoco G
    Oncologist; 2023 May; 28(5):e233-e241. PubMed ID: 36905579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.
    Wisdom AJ; Mowery YM; Riedel RF; Kirsch DG
    Cancer; 2018 Oct; 124(19):3819-3829. PubMed ID: 29723407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.
    Zhu MMT; Shenasa E; Nielsen TO
    Cancer Treat Rev; 2020 Dec; 91():102115. PubMed ID: 33130422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Therapy for Sarcomas.
    Anderson PM
    Adv Exp Med Biol; 2017; 995():127-140. PubMed ID: 28321815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Virus-Directed Therapy in Soft Tissue Sarcoma.
    Chaudhary H; D'Angelo S
    Curr Treat Options Oncol; 2022 Mar; 23(3):404-414. PubMed ID: 35258792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From vision to reality: deploying the immune system for treatment of sarcoma.
    Wilky BA; Goldberg JM
    Discov Med; 2017 Jan; 23(124):61-74. PubMed ID: 28245428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas.
    Dancsok AR; Setsu N; Gao D; Blay JY; Thomas D; Maki RG; Nielsen TO; Demicco EG
    Mod Pathol; 2019 Dec; 32(12):1772-1785. PubMed ID: 31263176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Determinants of Soft Tissue Sarcoma Immunity: Targets for Immune Intervention.
    Tazzari M; Bergamaschi L; De Vita A; Collini P; Barisella M; Bertolotti A; Ibrahim T; Pasquali S; Castelli C; Vallacchi V
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.